The extent of an exogenously administered bioactive molecule's sustained availability in the intended final site of action determines its potency and efficacy. Drug Delivery strategies have contributed to the conversion of potential therapeutics into effective treatments. DDSs are pharmaceutical formulations or systems that aid in the targeted delivery and/or controlled release (CR) of therapeutic agents in living organisms. Potential physical-chemical or enzymatic disruptions of the therapeutic agent are reduced by enclosing the molecules in a protective shell-like structure. DDSs regulate the rate of drug release and absorption, as well as the therapeutic and adverse effects of the drug. Ideal DDSs assure that the active medication is present at the site of action for the duration required by the patient. Delivery techniques and technologies swiftly changed to accommodate changing drug delivery needs as the therapeutic landscape altered.
- Controlled Drug Delivery System
- Ocular Drug Delivery System
- 2D & 3D Printing in Drug Delivery
- Drug Delivery: Devices and Equipment
- Nano Drug Delivery Systems
Howard I Maibach
University of California, United States
A C Matin
Stanford University, United States
Consolato M Sergi
University of Ottawa, Canada
Luis Jesus Villarreal Gomez
Autonomous University of Baja California, Mexico
Luis Jesus Villarreal Gomez
Autonomous University of Baja California, Mexico
Richard Denk
SKAN AG, Switzerland
Stefania Raimondo
University of Palermo, Italy
Manuel Narvaez Pelaez
University of Malaga, Spain
Merita Kucuku
Freelance consultant, Albania
Saliha Koc Aslan
Acibadem Healthcare Group, TurkeySubmit your abstract Today
Title : Pathology and patient safety: The vital role of electronic medical record and pathology informatics in error reduction and precision medicine
Consolato M Sergi, University of Ottawa, Canada
Title : mRNA-based systemically delivered directed gene therapy using nanomaterials
A C Matin, Stanford University, United States
Title : Role of nanoformulations in treating Cystic Fibrosis
Bhupendra Gopalbhai Prajapati, Shree S.K.Patel College of Pharmaceutical Education and Research, India
Title : EU GMP annex1 barrier system and PIC/s annex 2A on cell and gene therapy
Richard Denk, SKAN AG, Switzerland
Title : Pro and con to dermpharm and tox assays- 2023
Howard I Maibach, University of California, United States
Title : Dual GIP/GLP-1 receptor stimulation in treatment of type 2 diabetes mellitus – The ground-breaking 'twincretin' approach
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Mucoadhesive electrospun fibrous systems for the fast and sustained delivery of drugs
Luis Jesus Villarreal Gomez, Autonomous University of Baja California, Mexico
Title : Extracellular vesicles as delivery vehicles of therapeutic compounds
Stefania Raimondo, University of Palermo, Italy
Title : Pediatric brain on cannabinoids: Adverse effects of cannabinoid products in children and adolescents
Peter B Chase, Essentia Health- St. Mary's Medical Center, United States
Title : EBV latent membrane protein 1 augments gammer-delta T cell cytotoxicity against nasopharyngeal carcinoma by induction of butyrophilin molecules
Yue liu, Hong Kong Baptist University, China